Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41
Kyntra Bio Inc KYNB
$6.94
▼ -0.86%
($-0.06)
🎈 Low Float
Open
$7.01
Prev Close
$7.00
Day Range
$6.90 – $7.01
52W Range
$6.32 – $12.58
Market Cap
$28.10M
P/E (TTM)
0.15
Beta
1.03
EPS (TTM)
$45.30
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-11-14 |
| Shares Out. | 4,050,000 |
| Website | kyntrabio.com/home ↗ |
| Phone | 14159781200 |
| Employees | 34 |
| Revenue | -$1.5M |
| Gross Profit | -$1.5M |
| Net Income | $12.0M |
| Free Cash Flow | -$38.1M |
| Total Assets | $101.1M |
| Total Liabilities | $109.2M |
| Equity | -$29.6M |
About Kyntra Bio Inc
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Kyntra Bio Inc is a publicly traded company under the ticker symbol KYNB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-09-01)